Clinical science expertise and longstanding operational experience in global clinical trials is the driving force at MedAvante
Virgil operates on a highly configurable platform with applications for tablet devices used by clinicians and hand-held devices used by patients and observers, allowing direct digital capture and automated upload of eSource data from unique context-sensitive electronic clinical outcome assessment (eCOA) forms. Calling upon its strong scientific credentials, MedAvante builds in programmed clinical guidance to standardize patient assessment in real time and improve the accuracy of scoring.
A recent study compared the use of paper-based outcome assessments with Virgil in clinical trials of treatments for psychiatric and neurodegenerative disorders. The results showed that assessments administered with Virgil showed far fewer errors that those conducted with paper and pen, ranging from 57 to 94 percent fewer errors across four commonly used rating scales.
Ian Neilson, Senior VP of Global IT, MedAvante, says, “With Virgil, we are leading the way to a paperless future of stronger signal detection, more efficient workflows, and higher-quality data in clinical trials by matching scientific leadership and clinical expertise with leading-edge technologies and methodologies.”
Building on its record of collecting more than three and a half million pages of eSource data over eight years without losing a single data element, MedAvante continues to add features and functions to keep pace with changes in life science and technology. MedAvante ensures all data is fully encrypted, right down to the memory card used as a temporary backup by the tablet application, and ensures that data is handled in full compliance with European and U.S. privacy regulations.
“With more than 687,000 completed assessments of 56,000 clinical trial subjects across 233,000 study visits, our source data has been accepted by both the Food and Drug Administration and the European Medicines Agency in successful regulatory submissions,” notes Neilson. “Virgil will be used to collect millions of clinical outcome assessments in global trials across a variety of patient populations over the next few years, and data mining and machine learning will increase its value by opening limitless possibilities for new discoveries in life sciences.”